TCGA-60-2710-01A-01R-0851-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.540
- E2F_TARGETS+0.510
- MITOTIC_SPINDLE+0.510
- TGF_BETA_SIGNALING+0.500
- PI3K_AKT_MTOR_SIGNALING+0.470
- UV_RESPONSE_DN+0.340
- WNT_BETA_CATENIN_SIGNALING+0.330
- APICAL_SURFACE+0.280
- MTORC1_SIGNALING+0.280
- CHOLESTEROL_HOMEOSTASIS+0.270
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.260
- SPERMATOGENESIS-0.170
- OXIDATIVE_PHOSPHORYLATION-0.150
- ALLOGRAFT_REJECTION-0.110
- ANGIOGENESIS-0.060
- BILE_ACID_METABOLISM-0.060
- COAGULATION-0.040
- KRAS_SIGNALING_DN-0.040
- IL6_JAK_STAT3_SIGNALING-0.030
- MYOGENESIS-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8666-01A-11R-2403-07 | — | cohortSQ1 | 0.852 |
| 2 | TCGA-GD-A3OQ-01A-32R-A220-07 | — | — | 0.845 |
| 3 | TCGA-FD-A3N5-01A-11R-A21D-07 | — | — | 0.843 |
| 4 | TCGA-34-8455-01A-11R-2326-07 | — | cohortSQ1 | 0.821 |
| 5 | TCGA-G2-A3IB-01A-11R-A20F-07 | — | — | 0.817 |
| 6 | SRR13311157 | — | — | 0.806 |
| 7 | SRR13311182 | — | — | 0.803 |
| 8 | 5282B52E-8573-4FC0-9BED-420AE3D2B096 | — | — | 0.802 |
| 9 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.799 |
| 10 | TCGA-HQ-A5NE-01A-12R-A28M-07 | — | — | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.510 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.470 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |